相似文献
1
Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading.
Br J Cancer. 1990 Jul;62(1):142-6. doi: 10.1038/bjc.1990.247.
2
Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
Anticancer Res. 1992 May-Jun;12(3):677-82.
3
Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers.
Br J Cancer. 1996 Jun;73(12):1545-51. doi: 10.1038/bjc.1996.291.
4
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Br J Cancer. 1999 Oct;81(3):490-5. doi: 10.1038/sj.bjc.6690720.
5
Histological grade and steroid receptor content of primary breast cancer--impact on prognosis and possible modes of action.
Br J Cancer. 1988 Oct;58(4):480-6. doi: 10.1038/bjc.1988.245.
6
Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Anticancer Res. 1997 Mar-Apr;17(2B):1417-23.
7
Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
Anticancer Res. 1997 Jul-Aug;17(4B):3091-7.
8
Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
J Clin Pathol. 2017 Nov;70(11):954-960. doi: 10.1136/jclinpath-2016-204304. Epub 2017 Apr 17.
9
Steroid hormone receptors in the management of human breast cancer.
Ann Clin Res. 1980 Oct;12(5):202-7.
10
Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.
J Clin Pathol. 1999 Aug;52(8):604-11. doi: 10.1136/jcp.52.8.604.
引用本文的文献
1
Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
BMC Cancer. 2021 May 31;21(1):644. doi: 10.1186/s12885-021-08318-1.
2
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Breast Cancer Res Treat. 2020 Nov;184(1):23-35. doi: 10.1007/s10549-020-05782-4. Epub 2020 Aug 11.
3
Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment.
Br J Cancer. 2018 Aug;119(5):572-579. doi: 10.1038/s41416-018-0197-4. Epub 2018 Jul 23.
4
Effecst of Patho- Biological Factors on the Survival of Recurrent Breast Cancer Cases.
Asian Pac J Cancer Prev. 2018 Apr 25;19(4):949-953. doi: 10.22034/APJCP.2018.19.4.949.
5
High Expression of Sphingosine Kinase 1 in Estrogen and Progesterone Receptors-Negative Breast Cancer.
Iran J Pathol. 2017 Summer;12(3):218-224. Epub 2017 May 30.
6
Novel Strategies to Improve the Endocrine Therapy of Breast Cancer.
Oncol Rev. 2017 May 16;11(1):323. doi: 10.4081/oncol.2017.323. eCollection 2017 Mar 3.
7
Monocytes and macrophages, implications for breast cancer migration and stem cell-like activity and treatment.
Oncotarget. 2015 Jun 10;6(16):14687-99. doi: 10.18632/oncotarget.4189.
8
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.
World J Clin Oncol. 2014 Dec 10;5(5):990-1001. doi: 10.5306/wjco.v5.i5.990.
9
Co-ordination of cell cycle, migration and stem cell-like activity in breast cancer.
Oncotarget. 2014 Sep 15;5(17):7833-42. doi: 10.18632/oncotarget.2312.
10
Prognostic factors and survival in metastatic breast cancer: A single institution experience.
Rep Pract Oncol Radiother. 2013 Feb 14;18(3):127-32. doi: 10.1016/j.rpor.2013.01.001.
本文引用的文献
1
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.
Br J Cancer. 1957 Sep;11(3):359-77. doi: 10.1038/bjc.1957.43.
2
The value of estrogen and progesterone receptors in the treatment of breast cancer.
Cancer. 1980 Dec 15;46(12 Suppl):2884-8. doi: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u.
3
Relationship between primary breast tumor receptor status and patient survival.
Cancer. 1980 Dec 15;46(12 Suppl):2765-9. doi: 10.1002/1097-0142(19801215)46:12+<2765::aid-cncr2820461404>3.0.co;2-c.
4
Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer.
Eur J Cancer (1965). 1981 Apr;17(4):449-53. doi: 10.1016/0014-2964(81)90254-1.
5
Prognostic factors in metastatic breast cancer.
Cancer Clin Trials. 1981 Fall;4(3):237-47.
6
Survival after recurrence of breast cancer.
Can Med Assoc J. 1981 Jun 15;124(12):1591-5.
7
The value of prognostic parameters for the stratification of advanced breast cancer patients.
J Cancer Res Clin Oncol. 1982;102(3):289-99. doi: 10.1007/BF00411349.
8
Female sex steroid receptor status in primary and metastatic breast carcinoma and its relationship to serum steroid peptide hormone levels.
Int J Cancer. 1980 Jul 15;26(1):13-21. doi: 10.1002/ijc.2910260104.
9
The metastasis-free interval following curative treatment for breast cancer.
Int J Radiat Oncol Biol Phys. 1984 Jan;10(1):63-7. doi: 10.1016/0360-3016(84)90413-9.
10
Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure.
Cancer. 1984 Feb 1;53(3 Suppl):712-23. doi: 10.1002/1097-0142(19840201)53:3+<712::aid-cncr2820531320>3.0.co;2-i.
Zotero 插件